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ABSTRACT
The use of granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood as a source of stem cells
has resulted in a high incidence of severe chronic graft-versus-host disease (cGVHD), which compromises the
outcome of clinical allogeneic stem cell transplantation. We have studied the effect of G-CSF on both immune
complex and fibrotic cGVHD directed to major (DBA/23 B6D2F1) or minor (B10.D23 BALB/c) histocom-
patibility antigens. In both models, donor pretreatment with G-CSF reduced cGVHD mortality in association
with type 2 differentiation. However, after escalation of the donor T-cell dose, scleroderma occurred in 90%
of the recipients of grafts from G-CSF–treated donors. In contrast, only 11% of the recipients of control grafts
developed scleroderma, and the severity of hepatic cGVHD was also reduced. Mixing studies confirmed that
in the presence of high donor T-cell doses, the severity of scleroderma was determined by the non–T-cell
fraction of grafts from G-CSF–treated donors. These data confirm that the induction of cGVHD after donor
treatment with G-CSF is dependent on the transfer of large numbers of donor T cells in conjunction with a
putatively expanded myeloid lineage, providing a further rationale for the limitation of cell dose in allogeneic
stem cell transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
urrently indicated in the treatment of a number of
alignant and nonmalignant diseases. However, use
f the procedure is limited by its serious complica-
ions, the most common of which is graft-versus-host
isease (GVHD). Recently, the transplantation of
tem cells that are collected from the peripheral blood
f granulocyte colony-stimulating factor (G-CSF)–
reated donors (peripheral blood stem cell transplan-
ation [PBSCT]) has become widespread. GVHD re-
ains the major limitation of both procedures v
B&MThereafter termed stem cell transplantation [SCT]).
VHD in the ﬁrst 100 days of SCT is termed acute
VHD (aGVHD) and occurs in most SCT recipients,
amaging the skin, gastrointestinal (GI) tract, and
iver. GVHDmore than 100 days after SCT is termed
hronic GVHD (cGVHD) and may be limited (to the
kin, liver, or both) or extensive (involving the liver,
kin, and additional organs, particularly the mouth,
yes, and lung). Extensive cGVHD has a major neg-
tive effect on survival and quality of life after PBSCT,
ecessitating prolonged and poorly effective immuno-
uppressive therapy. Clinical risk factors for the de-
elopment of cGVHD include increasing age of donor
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3nd recipient, prior aGVHD, and second transplanta-
ion [1-4].
It has recently become clear that extensive
GVHD is more frequent after PBSCT than after
raditional BMT [5-7]. Even so, allogeneic PBSCT is
ssociated with improved rates of immune and hema-
opoietic reconstitution, reduced transplant-related
ortality, and improved leukemia eradication relative
o BMT [8]. For these reasons, PBSCT has become
he procedure of choice for the treatment of advanced
ematologic malignancies, and the transplant commu-
ity must now meet the challenge of improving strat-
gies to both prevent and treat cGVHD. Data from
linical PBSCT have associated the incidence of
GVHD with a number of graft-related factors, the
ost consistent of which is CD34 number [9]. Studies
ave also suggested a relationship between type 2
-cell phenotype, large numbers of type 2 dendritic
ells, and protection from cGVHD [10,11]. Previous
tudies have conﬁrmed that G-CSF alters the capacity
f dendritic cells and monocytes to induce inﬂamma-
ory responses in vitro [12,13], although a causal re-
ationship between these effects and the inhibition of
VHD remains unproven at this time.
Chronic GVHD is characterized by autoantibody
eneration and scleroderma and has been suggested as
T-helper type 2 (Th2)–dominant disease process
14]. G-CSF is known to alter T-cell function [15],
nd PBSCT products contain 10 to 20 times the
umber of T cells relative to bone marrow grafts, both
f which may increase cGVHD. Furthermore, G-CSF
as been shown to induce Th2 differentiation in do-
or T cells before SCT, and this been suggested to be
major protective mechanism from aGVHD in this
etting [16]. In support of this, administration of other
ytokines that induce Th2 differentiation either in
ivo [17] or in vitro [18] also protect from aGVHD.
owever, it is unclear as to whether this change in
-cell differentiation induced by G-CSF before SCT
s indicative of T-cell differentiation after SCT or
lays any causative role in the high rate of cGVHD
een after PBSCT.
We have examined the ability of stem cell grafts
obilized by G-CSF to induce cGVHD and the
echanisms therein. Our data conﬁrm that donor
retreatment with G-CSF results in donor Th2 dif-
erentiation after SCT but that this phenotype is pro-
ective from both aGVHD and cGVHD when low
umbers of donor T cells are transplanted. In con-
rast, escalation of the donor T-cell dose results in
igh rates of cGVHD when the graft also contains a
on–T-cell lineage that has been expanded or modi-
ed by G-CSF. These data conﬁrm that the develop-
ent of cGVHD after allogeneic SCT is dependent
n the transfer of large numbers of donor T cells in
onjunction with a putatively expanded myeloid lin-
age. b
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ice
Female C57BL/6 (B6, H-2b, Ly-5.2), B6 ptprca
y-5a (H-2b, Ly-5.1), B6D2F1 (H-2b/d, Ly-5.2),
10.D2 (H-2d), DBA/2, and BALB/c (H-2d) mice
ere purchased from the Australian Research Centre
Western Australia, Australia). The age of mice used
s BMT recipients ranged between 8 and 14 weeks.
ice were housed in sterilized microisolator cages and
eceived ﬁltered water and normal chow or autoclaved
rinking water after BMT.
ytokine Treatment
Recombinant human G-CSF (Amgen, Thousand
aks, CA) or control diluent was diluted in 1 g/mL
f murine serum albumin in phosphate-buffered saline
PBS) before injection. Mice were injected subcutane-
usly with G-CSF (2 g per animal per day) or diluent
nce daily from day 6 to day 1.
one Marrow Transplantation
Mice underwent transplantation according to a
tandard protocol that has been described previously
16,19]. Brieﬂy, on day 1, BALB/c recipient mice
eceived 600 cGy of total body irradiation (cesium 137
ource at 108 cGy/min), which was split into 2 doses
eparated by 3 hours to minimize GI toxicity. B6D2F1
ecipients were not irradiated. Donor spleens were
ashed, and then whole unseparated spleen cells (5 
07 B6 or 9  107 DBA/2) were resuspended in 0.25
L of Leibovitz L-15 media (Gibco BRL, Gaithers-
urg MD) and injected intravenously into recipients.
urvival was monitored daily, and the recipient’s body
eight and GVHD clinical score were measured
eekly. Donor cell engraftment in the B63 B6D2F1
odel of aGVHD was determined by examining the
roportion of Ly-5.1/(Ly-5.2  Ly-5.1) cells in
eripheral blood or spleen after transplantation. Do-
or cell engraftment in the DBA/23 B6D2F1 model
f cGVHD was determined by examining the propor-
ion of H-2b-negative, lineage-positive cells.
ssessment of GVHD
The degree of systemic GVHD was assessed by a
coring system that sums changes in 5 clinical param-
ters: weight loss, posture (hunching), activity, fur
exture, and skin integrity (maximum index  10)
17,20-22]. Individual mice were ear-tagged and
raded weekly from 0 to 2 for each criterion without
nowledge of treatment group. Animals with severe
linical GVHD (scores 6) were killed according to
thical guidelines, and the day of death was deemed to
e the following day. Proteinuria was determined
eekly after day 100 by using Multistix (Bayer, New-
ury, Berkshire, UK). A cutaneous clinical score was
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Chronic GVHD after G-CSF–Mobilized Allogeneic SCT
Blso generated by summation of the scores for fur and
kin from individual animals. The descriptors for scor-
ng were as follows: (1) fur texture—0, normal; 0.5,
artial ventral fur rufﬂing; 1.0, complete ventral fur
ufﬂing; 1.5, complete ventral fur rufﬂing and partial
orsal fur rufﬂing; and 2.0, diffuse ventral and dorsal
ur rufﬂing; (2) skin integrity—0, normal; 0.5, scaling
f paws, tail, or ears and loss of fur 1 cm2; 1.0, loss
f fur between 1 and 2 cm2; 1.5, loss of fur 2 cm2;
nd 2.0, loss of fur with cutaneous ulceration.
luorescence-Activated Cell Sorting Analysis
Fluorescein isothiocyanate–conjugated monoclo-
al antibodies (mAb) to mouse Ly-5.1 and Ly-5.2
ntigens; ﬂuorescein isothiocyanate–conjugated mAb
o CD4, CD8, CD11c, class II, CD3, GR-1, CD11b,
nd B220; and identical phycoerythrin-conjugated
Ab were purchased from PharMingen (San Diego,
A). Cells were ﬁrst blocked with mAb 2.4G2 for 15
inutes at 4°C, followed by the relevant conjugated
Ab for 30 minutes at 4°C. Finally, cells were washed
wice with PBS/0.2% bovine serum albumin, ﬁxed
ith PBS/1% paraformaldehyde, and analyzed by
ACScalibur (Becton Dickinson, Franklin Lakes, NJ).
ell Cultures
Culture media additives were purchased from
ibco BRL, and medium was purchased from Sigma
St. Louis, MO). Cell culture was performed in 10%
etal calf serum/Dulbecco modiﬁed Eagle medium
day 7 cultures) supplemented with penicillin 50
/mL, streptomycin 50 g/mL, l-glutamine 2
mol/L, sodium pyruvate 1 mmol/L, nonessential
mino acid 0.1 mmol/L, -mercaptoethanol 0.02
mol/L, and 10 mmol/L 4-(2-hydroxyethyl)-1-
iperazineethanesulfonic acid, pH 7.75, at 37°C in a
umidiﬁed incubator supplemented with 5% CO2. In
xperiments of T-cell function ex vivo, splenocytes
ere removed from animals 7 to 10 days after trans-
lantation, and 3 to 6 spleens were combined from
ach group. In separation experiments, CD4 and
D8 cells were positively selected from splenocyte
opulations by using ﬂuorescence-activated cell sort-
ng (FACS Vantage; Becton Dickinson) with pro-
idium iodide to exclude nonviable cells. H-2b was
lso used to exclude host T cells in the DBA/2 3
6D2F1 system. After selection, positive and negative
ractions had 1% contamination of opposing CD4
r CD8 cells. These cells were plated in 96-well
at-bottom plates with platebound anti-CD3 and
CD28 mAbs (both 10 g/mL).
ytokine Enzyme-Linked Immunosorbent Assays
The antibodies used in the interferon (IFN)–	,
nterleukin (IL)–10, and IL-4 assays were purchased
rom PharMingen. All assays were performed accord- s
B&MTng to the manufacturer’s instructions. Supernatants
ere collected after 40 hours and stored at 70°C
ntil analysis. Samples were then thawed and diluted,
nd IFN-	, IL-10, and IL-4 proteins were captured by
he speciﬁc primary mAb and detected by biotin-
abeled secondary mAb followed by horseradish per-
xidase–conjugated streptavidin. The biotin-labeled
ssays were developed with tetramethylbenzidine sub-
trate (Kirkegaard and Perry Laboratories, Gaithers-
urg, MD). Plates were read at 450 nm by using a
icroplate reader (Bio-Rad, Hercules, CA). Recom-
inant cytokines (PharMingen) were used as standards
or enzyme-linked immunosorbent assays. Samples
nd standards were run in duplicate, and the sensitiv-
ty of the assays was 0.063 U/mL for IFN-	 and 15
g/mL for IL-10 and IL-4.
nti–Single-Stranded DNA Determination
Serum was frozen at –80°C until analysis. En-
yme-linked immunosorbent assay plates were coated
ith 10 g/mL of methylated bovine serum albumin
or 60 minutes at room temperature and then washed.
lates were then incubated with denatured calf thy-
us (10 g/mL), washed, and blocked in 5% fetal calf
erum/PBS overnight. Test serum was added at semi–
og dilutions for 3 hours the next day after further
ashing. Speciﬁc biotinylated anti-mouse isotype de-
ection antibodies were added (PharMingen), and
treptavidin/horseradish peroxidase was added in the
nal step. Plates were developed with O-phenylene-
iamine dihydrochloride substrate; reactions were
topped by the addition of HCl 2.5 mol/L and were
hen read at 490 nm. MRL/lpr serum was used as an
nternal control to normalize data analyzed at differ-
nt time points. The optical density of MRL/lpr se-
um diluted at 1:644 and 1:2120 was used to deter-
ine the titer of immunoglobulin (Ig)G1 and IgG2
,
espectively, in test samples.
istology
Formalin-preserved distal small bowel was embed-
ed in parafﬁn, and 5-m-thick sections were stained
ith hematoxylin and eosin for histologic examina-
ion. Slides were coded and examined in a blinded
ashion by 1 individual (A.D.C.), who used a semi-
uantitative scoring system for abnormalities known
o be associated with GVHD [17,21,22]. For the skin,
ermal collagen thickness was measured at a minimum
f 5 points and averaged. Scleroderma was assigned to
he animal when dermal collagen thickness was
reater than the average  3SD of the syngeneic
ontrol group. Six parameters were scored from 0 to 4
nd summed to assign a dermal inﬂammatory score
dermal inﬂammation, keratinocyte apoptosis, cutane-
us blistering, epidermal inﬂammation, dermal ﬁbro-
is, and subcutaneous ﬁbrosis). The collagen score was
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3etermined by blinded examination of Masson
richrome staining of skin (graded from 1 to 5). The
escriptors were as follows: 1, 50% density collagen
ithout dermal expansion; 2, 50% density collagen
ithout dermal expansion; 3, 80% density collagen
ith dermal expansion125% of syngeneic; 4,80%
ensity collagen, dermal thickness 125% to 200% of
yngeneic, or both; and 5, 80% density collagen,
ermal thickness 200% of syngeneic, or both. No
ifferences were seen in cutaneous parameters of
GVHD in syngeneic recipients regardless of the do-
or cell dose or pretreatment (with G-CSF). For the
iver, 10 parameters were scored that reﬂected GVHD
f the portal tract (portal tract expansion by inﬂam-
atory cell inﬁltrate, lymphocytic inﬁltrate of bile
ucts, bile duct epithelial cell apoptosis, bile duct
pithelial cell sloughing, and vascular endothelialitis)
nd hepatic parenchyma (parenchymal apoptosis, pa-
enchymal microabscesses, parenchymal mitotic ﬁg-
res, hepatocellular cholestasis, and hepatocellular
teatosis). For GI tract analysis, 7 parameters each
ere scored for small bowel (villous blunting, crypt
egeneration, crypt epithelial cell apoptosis, crypt loss,
uminal sloughing of cellular debris, lamina propria
nﬂammatory cell inﬁltrate, and mucosal ulceration).
he scoring system for each parameter denoted 0 as
ormal, 0.5 as focal and rare, 1 as focal and mild, 2 as
iffuse and mild, 3 as diffuse and moderate, and 4 as
iffuse and severe, as previously published in human
23,24] and experimental [17,21,22] GVHD histology.
cores were added to provide a total score of 24 for
he skin, 28 for the small bowel, and 40 for the liver.
tatistical Analysis
Survival curves were plotted by using Kaplan-
eier estimates and were compared by log-rank anal-
sis. The Mann-Whitney U test was used for the
tatistical analysis of cytokine data and clinical scores.
 .05 was considered statistically signiﬁcant.
ESULTS
onor Pretreatment with G-CSF Reduces Both
GVHD and cGVHD in Nonirradiated Models
We ﬁrst examined the effects of G-CSF mobili-
ation in well-established murine SCT models of
GVHD (B6 Ly5a3 B6D2F1) or cGVHD (DBA/23
6D2F1) that induce GVHD to major and minor
istocompatibility antigens (HA) without prior irradi-
tion of the recipient. Although these models use the
pleen rather than peripheral blood as a stem cell
ource, their validity has been established by informa-
ive data indicating beneﬁcial effects of G-CSF on
oth GVHD and graft-versus-leukemia [12,15]; this
as since been conﬁrmed clinically [8]. In these stud-
es, allogeneic donor B6 or DBA/2 animals received k
76aily injections of either control diluent or G-CSF (2
g per animal), administered for 6 days. We have
reviously shown that this treatment schedule results
n similar proportions of T cells in the spleen of B6
onors [15], and this was also true of DBA/2 donors
CD4 T cells, 8.7% 0.6% versus 7.2% 0.5%; P
09; CD8 T cells, 3.6%  0.3% versus 2.9%  0.2%;
 .17). Splenocytes were harvested on day 7, and
6D2F1 recipient mice underwent transplantation
ith 5  107 or 9  107 splenocytes from B6 or
BA/2 donors, respectively. In preliminary experi-
ents, these doses reliably induced GVHD in recip-
ents of control-treated splenocytes. As shown in Fig-
re 1A, aGVHD induced in the acute model was
evere; 50% of recipients of control splenocytes died
ithin 8 weeks with characteristic features of GVHD
weight loss, hunching, fur rufﬂing, and so on), as
etermined by the clinical score. In contrast, 100% of
ecipients of non-GVHD controls that underwent
ransplantation with syngeneic splenocytes survived.
llogeneic SCT recipients of G-CSF splenocytes had
signiﬁcantly improved survival (95% versus 50%;
 .01) and reduced clinical scores compared with
ecipients of allogeneic control splenocytes. In the
GVHD model, allogeneic SCT recipients of
-CSF–treated DBA/2 splenocytes also had signiﬁ-
antly improved survival (85% versus 45%; P  .05;
igure 1B). In addition, the incidence of proteinuria
as reduced at day 180 in recipients of G-CSF grafts
ompared with recipients of allogeneic control spleno-
ytes (25% versus 80%, respectively; P  .01), al-
hough the rate at which disease developed was un-
hanged (the median time to proteinuria was 90 versus
8 days, respectively).
Donor T-cell engraftment in the acute model at
ay 28 after SCT was 94.7%  1.4% in recipients of
ontrol splenocytes and 95.4%  0.7% in recipients
f G-CSF splenocytes. The cGVHD model is char-
cterized by low-level donor T-cell engraftment,
hich provides aberrant B-cell help and results in
utoantibody generation. Donor CD4 and CD8 en-
raftment was equivalent in recipients of G-CSF and
ontrol-treated splenocytes. The expansion of host B
ells in the spleen of animals 14 days after SCT was
dentical (Table 1), as was host B-cell activation, as
etermined by major histocompatibility complex class
I expression. These data conﬁrm that donor treat-
ent with G-CSF did not induce quantitative differ-
nces in donor T-cell engraftment or host B-cell ac-
ivation and expansion.
onor Pretreatment with G-CSF Results in Th2
ifferentiation after SCT
The preferential differentiation of donor T cells in
type 2 fashion is known to reduce the severity of
GVHD [25]. Donor pretreatment with G-CSF is
nown to be capable of inducing Th2 differentiation
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Bn response to alloantigen in vitro [16,26], but this has
ot been demonstrated in vivo, either clinically or
xperimentally. Because it has been proposed that
GVHD is a Th2-dominant disease process [27], we
ext studied the relative states of immune deviation in
he cGVHDmodel in vivo. In the ﬁrst instance, donor
D4 cells (H-2b negative) were sorted from spleen 14
ays after SCT by ﬂuorescence-activated cell sorting
nd were stimulated in vitro with CD3 and CD28. As
hown in Figure 2, donor CD4 T cells from recipients
f G-CSF–treated donor cells produced less IFN-	
nd more IL-4 than donor CD4 T cells from recipi-
igure 1. Donor pretreatment with G-CSF prevents acute and chr
imilar experiments. Naive B6 (A) or DBA/2 (B) mice were tre
onirradiated B6D2F1 recipients underwent transplantation with
ontrol group underwent transplantation with syngeneic control-tr
urvival and weekly for clinical score (A) and proteinuria (B). **P 
able 1. T-Cell Engraftment and B-Cell Activation
Variable
Control Allogeneic
Donor Host
cell
CD4 4.7  1.2 23.6  1.9
CD8 2.9  1.0 20.7  1.2
cell
B220 60.7  8.3
Class II expression 301  43
aive DBA (H-2d) mice received control diluent or G-CSF, and sp
Fourteen days later, splenocytes from transplant recipients (n 
of donor (H-2b negative) T and B cells were determined per splee
intensity of class II expression on H-2b positive B cells.P  .05 versus G-CSF and control allogeneic. Differences between allog
B&MTnts of control treated donor cells. It is interesting to
ote that the cytokine proﬁles of host CD4 T cells
H-2b positive) were identical (data not shown), con-
istent with the role of G-CSF in determining T-cell
ifferentiation while within the donor. This model is
haracterized by high levels of autoantibody that are
roduced within 2 weeks of transplantation and peak
t 6 weeks. We therefore characterized the quantity
nd quality of autoantibodies produced by the 2 allo-
eneic groups at these time points. As shown in Figure
B, the transplantation of splenocytes from G-CSF–
reated donors resulted in a signiﬁcant decrease in the
VHD. Survival curves are by Kaplan-Meier analysis pooled from 2
ith control diluent (E; n  17-18) or G-CSF (F; n  15-19).
arated splenocytes, and survival was noted daily. A non-GVHD
6D2F1 splenocytes (; n  8). Animals were monitored daily for
d *P  .05, control versus G-CSF.
G-CSF Allogeneic
Naive B6D2F1Donor Host
6.7  1.4 31.4  11.3 19.7  6.1*
2.4  1.5 23.2  6.5 11.5  2.1*
86.7  26.7 47.6  5.0*
348  26 149  32*
tes were transplanted into B6D2F1 mice as described in Methods.
re phenotyped by ﬂuorescence-activated cell sorting, and numbers
6). Host B-cell activation was determined by the mean ﬂuorescenceonic G
ated w
unsep
eated Blenocy
5) we
n (10eneic groups were not statistically different.
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3uantity of the type 1 (IgG2
) autoantibody isotype,
esulting in a marked reduction in the ratio of IgG2

o IgG1 isotypes, consistent with Th2 differentiation.
hese data suggest that donor pretreatment with G-
SF does indeed promote Th2 differentiation in vivo
uring cGVHD, but this is associated with a decrease
ather than an increase in the severity of disease in this
odel.
onor Pretreatment with G-CSF Reduces cGVHD
ortality Directed against Minor HA
The immune complex nephritis model, although
nformative, does not reﬂect the major clinical presen-
ations of cGVHD, which characteristically manifests
s hepatic and cutaneous scleroderma. To ensure that
he previous ﬁndings were predictive of scleroderma-
ous cGVHD, we next used a model of cGVHD
irected to isolated minor HA. B10.D2 donor mice
ere pretreated with G-CSF or control diluent as
igure 2. Donor pretreatment with G-CSF induces Th2 differen
ourteen days after SCT, spleens were removed from control (open
D4 T cells were sorted by ﬂuorescence-activated cell sorting a
ytokines were determined in culture supernatant as described in
xperiments. B, The isotype-speciﬁc anti-DNA antibody titer was d
 4-9) or G-CSF (closed bars; n 5-9) allogeneic SCT recipients
nimals were determined. The titer in nontransplanted age-matche
igure 3. Donor pretreatment with G-CSF prevents cGVHD mo
aplan-Meier analysis pooled from 6 similar experiments. Donor B1
07) from control (E; n  55) or G-CSF (F; n  51) were harveste
ice. Control-treated syngeneic spleen (; n  28) was transplant
cores were assessed by a scoring system that sums changes in 5 clin
kin integrity (maximum index  10) as described in Methods. *P  .05 a
78escribed previously. Splenocytes (2.5  107) were
hen transplanted into sublethally irradiated (600 cGy)
ecipient BALB/c mice, which differ from B10.D2
onors only at minor HA [28,29]. Spleen from G-
SF–treated donors contained equal numbers of T
ells but increased numbers of Gr-1 and CD11b cells
elative to control-treated donors, as previously de-
cribed [30]. Syngeneic control and G-CSF–treated
rafts from BALB/c donors were transplanted into
ALB/c recipients as non-GVHD controls. Donor
retreatment with G-CSF resulted in a 10-fold in-
rease in IL-4 and IL-10 from CD8 T cells and a
-fold increase from CD4 T cells after SCT in re-
ponse to mitogen (data not shown). As shown in
igure 3, SCT recipients of splenocytes from G-CSF–
reated donors had reduced GVHD mortality (8%
ersus 24%; P  .05) and clinical scores compared
ith recipients of grafts from control diluent–treated
nimals. Cutaneous manifestations of cGVHD were
after SCT. Mice underwent transplantation as in Figure 1B. A,
or G-CSF (closed bars) allogeneic SCT recipients (n  4). Donor
stimulated with platebound CD3 and CD28. Proliferation and
s. Data represent the mean  SE of triplicate wells from 1 of 2
ned in the sera at days 14 and 45 after SCT in control (open bars;
experiments, as described in Methods, and the ratios for individual
2F1 controls was 1:64. Results represent mean  SE; *P  .05.
and morbidity in a scleroderma model. A, Survival curves are by
ice were treated with G-CSF or control diluent. Splenocytes (2.5
ransplanted into sublethally irradiated (600 cGy) BALB/c recipient
non-GVHD control. *P  .04, G-CSF versus control. B, Clinical
rameters: weight loss, posture (hunching), activity, fur texture, andtiation
bars)
nd then
Method
etermi
from 2
d B6Drtality
0.D2 m
d and t
ed as a
ical pand **P  .01, G-CSF versus control.
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Chronic GVHD after G-CSF–Mobilized Allogeneic SCT
Bssessed by using the inﬂammatory score (which re-
ected the degree of cellular inﬁltrate and secondary
nﬂammatory changes), the density and thickness of
ermal collagen deposition, the dermal thickness, and
he number of individual animals per cohort that ful-
lled criteria for scleroderma of the skin. By using
hese 4 parameters, cutaneous scleroderma was in-
uced at an equivalent low level in both allogeneic
roups, and collagen deposition was moderately in-
reased in both groups relative to syngeneic controls
Table 2). These data suggest that the high incidence
f cGVHD seen with the transplantation of grafts
rom G-CSF–treated donors was not due to the trans-
er of donor T cells with a type 2 phenotype per se.
onor Pretreatment with G-CSF Induces
cleroderma Only after the Transfer of High
umbers of Donor T Cells
Because cGVHD after clinical PBSCT is associ-
ted with the transfer of very high numbers of G-
SF–modiﬁed donor T cells relative to BMT (10-fold
ncrease), we next studied the effects of T-cell dose on
he development of cGVHD. In these studies, donor
plenocytes were supplemented with 2.5  107 puri-
ed donor T cells from G-CSF–treated or control-
reated donors. Recipients of T cell–escalated grafts
rom G-CSF–treated donors universally developed
linical features of skin GVHD that were character-
zed by tail, ear, and paw thickening and desquamation
eading to loss of fur (Table 3). These features were
ot evident or were less severe in recipients of control
rafts (1.22 versus 2.09; P  .05). To determine
able 2. Cutaneous Chronic GVHD Histology
Variable
Control
Allogeneic
G-CSF
Allogeneic
Control
Syngeneic
linical skin score
(0-4) 1.07  0.15* 0.68  0.16* 0.00  0.00
nflammatory score
(0-24) 2.75  0.95* 3.64  1.14* 0.21  0.07
ollagen score
(1-5) 2.40  0.40* 2.80  0.40* 1.30  0.30
ermal thickness
(mm) 0.22  0.01 0.23  0.02 0.23  0.02
cleroderma 6% (n  16) 14% (n  14) 0% (n  13)
ice were transplanted with 2.5  107 splenocytes from donor
B10.D2 mice treated with diluent or G-CSF as described in
Methods. Clinical score was graded before death 6 weeks after
SCT. Liver and skin were embedded in parafﬁn and examined
by a histopathologist without knowledge of treatment groups
according to the parameters described in Methods. Scleroderma
was deﬁned as skin thickness more than average  3 SD of
syngeneic recipients. Data are derived from 2 experiments and
are expressed as meanSE.
P  .05 versus syngeneic recipients. Differences between alloge-
neic groups were not statistically signiﬁcant.hether donor pretreatment with G-CSF altered the †
B&MTevelopment of cGVHD histopathology in SCT re-
ipients, we determined the degree of cGVHD organ
amage by semiquantitative histopathology. As shown
n Table 3 and Figure 4, the recipients of G-CSF
rafts had a 50% increase in dermal thickness rela-
ive to recipients of allogeneic and syngeneic control-
reated splenocytes (P  .05). In conjunction with
ermal thickening, the inﬂammatory score was in-
reased 5-fold in recipients of allogeneic G-CSF–
reated grafts relative to control-treated allogeneic
rafts. Although recipients of control allogeneic grafts
id not develop overt dermal expansion, they had a
ild inﬂammatory cutaneous inﬁltrate and had in-
reased collagen deposition relative to syngeneic re-
ipients, consistent with mild cGVHD. Surprisingly,
0% of the recipients of grafts containing high num-
ers of T cells from G-CSF–treated donors had
cleroderma, whereas only 11% of the recipient T
ells from control donors fulﬁlled this criterion. He-
atic injury is a major manifestation of cGVHD, and
e used semiquantitative histology to analyze injury in
ransplant recipients 5 weeks after SCT. When high
oses of allogeneic T cells were transferred from do-
ors pretreated with G-CSF, hepatic GVHD was in-
reased relative to that in recipients of high numbers
f control T cells (Figure 5). The histologic parame-
ers discriminatory between groups were bile duct
ymphocytosis (1.3 0.2 versus 0.56 0.32; P .03),
epatocyte apoptosis (1.32  0.25 versus 0.5  0.2;
 .05), and lobular inﬂammation (1.64  0.2 versus
.4  0.25; P  .05).
able 3. Cutaneous Chronic GVHD Histology after Escalation of
onor T-Cell Dose
Variable
Control
Allogeneic
G-CSF
Allogeneic
G-CSF
Syngeneic
linical score (0-4) 1.22  0.21* 2.09  0.27* 0.00  0.00
nflammatory score
(0-24) 2.11  0.83 12.18  1.17† 0.50  0.35
ollagen score
(1-5) 3.20  0.20* 4.20  0.40* 1.30  0.30
ermal thickness
(mm) 0.25  0.01 0.35  0.03† 0.21  0.01
cleroderma 11% (n  9) 90% (n  10)† 0% (n  4)
llogeneic recipients were transplanted with splenocytes (2.5 107)
supplemented with puriﬁed T cells (2.5 107) from donor mice
treated with diluent or G-CSF as described in Methods. Syn-
geneic recipients received splenocytes supplemented with T
cells from G-CSF–treated BALB/c mice. Clinical score was
graded before death 6 weeks after SCT. Skin was embedded in
parafﬁn and examined by a histopathologist without knowledge
of treatment groups according to the parameters described in
Methods. Scleroderma was deﬁned as skin thickness more than
average  3SD of syngeneic recipients. Data are derived from 2
experiments and are expressed as meanSE.
P  .05 versus syngeneic recipients;
P  .02 versus control allogeneic and syngeneic recipients.
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3he Induction of Severe Sclerodermatous cGVHD
fter Donor Treatment with G-CSF Is Due to
ffects on the Non–T-Cell Compartment
We next asked whether the increased severity of
GVHD in recipients of G-CSF–treated grafts was
elated primarily to the high dose of Th2 cells in
solation or was enhanced by the effect of G-CSF on
dditional non–T-cell populations (eg, myeloid cells).
ecipient mice underwent transplantation with T
ell–depleted spleen from control-treated or G-CSF–
reated donors with the addition of puriﬁed control or
-CSF–treated T cells. Recipients were scored for
utaneous GVHD severity and were monitored for
urvival and clinical score. Allogeneic recipients de-
eloped features of severe GVHD between day 30 and
0, and cutaneous clinical scores continued to increase
igure 4. Donor pretreatment with G-CSF induces cutaneous scler
ransplantation with grafts from syngeneic (A and D), control allog
ematoxylin and eosin (A-C) and Masson trichrome (which stains co
nimals that received grafts from G-CSF–treated donors had sclerod
eplacement of subdermal fat by collagen, and an intense inﬂammaefore death. Because the cutaneous clinical score m
80orrelates with the histologic inﬂammatory score and
ermal thickness (R2  0.52; P  .01), semiquantita-
ive histology was examined after death in allogeneic
ecipients to allow maximal time for histopathology to
evelop. As shown in Table 4, the addition of T cells
rom G-CSF–treated donors to T cell–depleted
pleen from control donors accelerated the rate of
VHD mortality relative to recipients of control-
reated T cells and control T cell–depleted spleen
P  .05). However, the severity of cutaneous and
epatic cGVHDwas not increased despite the transfer
f high numbers of G-CSF–modiﬁed T cells. In con-
rast, the addition of T cells from control-treated
onors to T cell–depleted spleen from G-CSF–
reated donors both accelerated mortality and resulted
n a signiﬁcant increase in the severity of cGVHD as
a after the transfer of high numbers of T cells. Animals underwent
B and E), or G-CSF allogeneic (C and F) donors. Representative
blue; D-F) stains are shown. Skin was harvested 6 weeks after SCT.
haracterized by increased density and expansion of dermal collagen,
ﬁltrate.oderm
eneic (
llagen
erma c
tory inanifested by clinical score and histopathology (Table
4
p
c
s
r
t
n
n
v
l
t
u
l
C
m
n
0
t
G
l
c
i
l
c
o
D
G
i
[
f
a
C
t
a
s
w
i
p
i
i
h
c
t
t
g
d
C
m
F
c
w
h
b
c
s
s
T
G
C
H
G
N
*
Chronic GVHD after G-CSF–Mobilized Allogeneic SCT
B). The severity of cutaneous cGVHD mirrored that
reviously seen with both G-CSF T-cell and non–T-
ell compartments at this time after SCT (Table 3),
uggesting that the non–T-cell fraction is primarily
esponsible for the induction of scleroderma rather
han Th2 differentiation per se. It is interesting to
ote that neither the G-CSF–modiﬁed T-cell nor the
on–T-cell compartment in isolation altered the se-
erity of postmortem GI GVHD (Table 4), which is
ikely to be the cause of universal mortality after the
ransplantation of the large numbers of donor T cells
sed in these experiments. Conversely, recipients of
igure 5. Donor pretreatment with G-CSF augments hepatic
GVHD after the transfer of high T-cell numbers. Animals under-
ent transplantation with high T-cell doses as in Table 3. Liver was
arvested 5 weeks after SCT, and hepatic cGVHD was determined
y semiquantitative histology as described in Methods. Open bar,
ontrol allogeneic, n  12; solid bar, G-CSF allogeneic, n  12;
haded bar, syngeneic, n  3. *P  .05, G-CSF allogeneic and
yngeneic versus control allogeneic.
able 4. The Effect of the G-CSF–Modiﬁed Non–T-Cell Compartmen
Variable
TCD Control 
Control T
VHD mortality (median day) 52
utaneous GVHD
Clinical score (0-4) 1.90  0.30
Inflammatory score (0-24) 6.20  2.40
Dermal thickness (mm) 0.27  0.02
epatic GVHD histology score 2.80  0.90
I tract GVHD histology score 11.50  1.40
R indicates not reached. Mice were transplanted with T-cell–deple
B10.D2 mice treated with diluent or G-CSF as described in Meth
clinical score was that before death. Postmortem liver, skin, and
without knowledge of treatment groups according to the paramP  .05 versus TCD control  control T recipients.
B&MTarge numbers of unseparated splenocytes from G-
SF–pretreated donors (12.5  107) had only 20%
ortality by day 45 (data not shown), although cuta-
eous GVHD was increased (skin thickness, 0.33 
.2 mm; inﬂammatory score, 8.8  1.3). Thus, the
ransfer of both T-cell and non–T-cell subsets from
-CSF–treated donors is important in combination to
imit GVHD mortality, but it results in an increase in
utaneous histopathology. These data suggest that the
ncrease in cGVHD seen after PBSCT occurs when
arge numbers of donor T cells are transferred in
onjunction with a non–T cell that has been expanded
r modiﬁed by G-CSF.
ISCUSSION
We have shown that donor pretreatment with
-CSF signiﬁcantly reduces the incidence of aGVHD
n an experimental SCT model both in irradiated
16,26] and, now, in nonirradiated hosts. We have
urther extended these studies to the cGVHD setting
nd demonstrated that donor pretreatment with G-
SF induces donor Th2 differentiation after SCT and
hat this is associated with reduced cGVHD mortality
nd morbidity. However, the increase in cGVHD
een after donor treatment with G-CSF occurs only
hen large numbers of donor T cells are transferred
n conjunction with a non–T cell that has been ex-
anded or modiﬁed by G-CSF.
Acute GVHD has been established as a Th1-dom-
nant disease, whereas the production of autoantibod-
es in both experimental models and clinical practice
as suggested that cGVHD is a Th2-dominant pro-
ess. It has been established that autoantibodies (par-
icularly those of an IgG2
 isotype) are pathogenic in
he nephritis model of cGVHD [31], as they are in
lomerulonephritis in the nontransplant setting. Our
ata demonstrate that donor pretreatment with G-
SF can prevent glomerulonephritis despite the pro-
otion of Th2 differentiation and that it is consistent
ronic GVHD
CD Control 
G-CSF T
TCD G-CSF 
Control T Syngeneic
44* 35* NR
2.00  0.60 3.75  0.25* 0.00  0.00
8.50  2.30 13  1.60 0.17  0.17
0.32  0.03 0.37  0.02* 0.20  0.01
4.40  1.70 7.80  1.40* 0.70  0.20
8.80  0.90 11.50  1.50 1.70  0.20
D) splenocytes (2 107) and puriﬁed T cells (3 107) from donor
 4-5 per allogeneic group and n 3 in syngeneic). The cutaneous
act were embedded in parafﬁn and examined by a histopathologist
escribed in Methods. Data are expressed as meanSE.t on Ch
T
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3ith the promotion of less pathogenic IgG1 autoan-
ibody isotypes (Figure 2) that are known to have a
educed capacity to induce renal disease [31]. This
nding is consistent with the prevention of spontane-
us nephritis in the MRL/lpr mouse by the adminis-
ration of G-CSF, although this seemed to be a dose-
ependent phenomenon that was related to the anti-
nﬂammatory properties of G-CSF rather than effects
n T-cell differentiation [32]. Although autoantibod-
es develop in association with cGVHD, any role in
he pathogenesis of scleroderma in clinical cGVHD
emains unproven.
The T-cell cytotoxic pathways (eg, perforin, gran-
ymes, Fas/Fas ligand, and other members of the
umor necrosis factor [TNF]-
 superfamily) all play a
ole in GVHD [33,34]. The induction of cGVHD in
he DBA/2 3 B6D2F1 lupus nephritis model has
een demonstrated to be the result of low antihost
ytotoxic T lymphocyte (CTL) frequency (in contrast
o the B6 3 B6D2F1 model of aGVHD) [35]. Thus,
he relative absence of antihost CTL prevents full
onor chimerism and eradication of host B cells in
xperimental models. This promotes the development
f low-level donor CD4 T cell-engraftment, which
rovides aberrant help to host B cells with subsequent
utoantibody production. In support of this, the ab-
ence of the cytotoxic protein perforin in donor T
ells promotes autoimmunity and B-cell hyperactivity
36], and impairment of donor Fas ligand–mediated
ytotoxicity has been previously demonstrated as a
athogenic factor in the induction of cGVHD [37].
imilarly, promotion of cytotoxicity by the induction
f IL-12 production or the administration of exoge-
ous IL-18 prevents the development of cGVHD
38,39]. Although donor pretreatment with G-CSF
eems to have little effect on CTL activity against host
ntigens, as determined by standard chromium release
ssays [16,26,30], it is possible that G-CSF alters the
requency of antihost CTL or alters the competency
f cytotoxicity pathways that are important in the
ontrol of B-cell function in vivo (eg, Fas/Fas ligand).
ecause such effects would not be demonstrable with
he cytotoxicity assay methods described to date
which primarily measure perforin activity), this will
equire study by more sensitive molecular methods. In
he B10.D2 3 BALB/c model, the CD4 fraction in
solation is capable of inducing most of the GVHD
athology, and so the effects of G-CSF on cytotoxicity
re less likely to be relevant to GVHD in this system
40,41].
The ability of G-CSF to alter T-cell cytokine
roﬁles has been previously documented, although the
hanges to T-cell differentiation have varied, and this
ay reﬂect differences in the dose and schedule of
-CSF used [16,26,42]. We have found that T cells
rom donors treated with G-CSF produce more IL-4
nd IL-10 to alloantigen and mitogen before SCT, o
82lthough we have seen blunting of all cytokine re-
ponses after SCT after high and prolonged doses of
-CSF [16,26,30]. To our knowledge, this is the ﬁrst
xperimental study demonstrating that donor pre-
reatment with G-CSF can induce Th2 differentiation
fter SCT. Th1 cells produce cytokines (especially
FN-	) that prime mononuclear cells to produce cy-
opathic quantities of inﬂammatory cytokines (TNF-

nd IL-1) after stimulation with lipopolysaccharide
43]. This is a major mechanism by which Th1 differ-
ntiation results in TNF-
 production and gut injury
uring aGVHD [27]. It is now clear that Th2 cyto-
ines are important in the induction of cutaneous and
epatic GVHD, because the prevention of Th2 cyto-
ine generation after SCT by using STAT-4 knock-
ut donors and eliminating tyrosine kinase–trans-
uced donor Th2 clones after SCT ameliorates
xperimental GVHD in these organs [44,45]. In ad-
ition, the prevention of IL-4 generation after SCT
rovides protection from GVHD [46]. Therefore,
oth Th1 and Th2 cytokines are important in the
nduction of GVHD, and the promotion of Th2 cy-
okine generation after SCT may therefore be ex-
ected to alter the presentation of GVHD rather than
revent its development. Together, these data suggest
hat Th2 differentiation reduces GVHD mortality
ecause of the limitation of early GI tract injury and
nﬂammatory cytokine production but may be less
ffective in preventing later hepatic and cutaneous
istopathology. Thus, the high numbers of G-CSF–
odiﬁed donor type 2 T cells transplanted during
linical PBSCT may be expected to induce a similar
evel of aGVHD as traditional BMT (with 10-fold less
ype 1 T cells) but to increase the development of
GVHD.
The induction of cutaneous scleroderma and he-
atic ﬁbrosis is well described in the B10.D2 3
ALB/c model and has been previously prevented by
process of oral tolerance to host splenocytes. This
esulted in high levels of IL-10 and reduced IFN-	 in
erum; this may reﬂect Th2 differentiation or the
nduction of T-cell regulation [28,29]. This is consis-
ent with the reduction in GVHD mortality seen in
ur studies in association with Th2 differentiation
fter G-CSF administration. However, the escalation
f donor T-cell dose in conjunction with the non–T-
ell population of the graft after G-CSF administra-
ion overwhelms this protective effect and results in
he induction of scleroderma. Given the nature of
-CSF, the non–T cell responsible for this effect is
ikely to be within an expanded or modiﬁed myeloid
ineage. G-CSF expands monocytes and basophils up
o 10-fold [47], and the development of cutaneous
GVHD is known to involve mast cells [48] that have
similar structure and function to basophils in the
nduction of allergic disease. Furthermore, the devel-
pment and degranulation of basophils and mast cells
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Bre in part controlled by the Th2 cytokines IL-4 and
L-10, which are in excess after SCT with G-CSF–
obilized grafts [49]. Degranulation of basophils and
ast cells results in the release of numerous ﬁbrogenic
ediators, including transforming growth factor-,
asic ﬁbroblast growth factor, and vascular endothelial
rowth factor. In the scleroderma model of cGVHD
eported by Zhang et al. [50] and McCormick et al.
51], low numbers of donor B10.D2 bone marrow and
plenocytes were transplanted into irradiated BALB/c
ecipients, and the subsequent induction of cutaneous
nd pulmonary ﬁbrosis was associated with the pro-
uction of transforming growth factor- by CD11b
ononuclear cells. It is therefore likely that G-CSF
ontributes to the severity of cGVHD by expanding
onor myeloid populations while providing a Th2
ytokine milieu conducive to ongoing differentiation
nd degranulation of these cells with subsequent ﬁ-
rosis. In support of this, inhibitors of IgE binding to
cR1 receptors on mast cells inhibit the development
f GVHD [52].
Allogeneic SCT with G-CSF–mobilized stem
ells represents a major advance in the management of
ematologic malignancies because of improved rates
f hematopoietic reconstitution and leukemia clear-
nce relative to traditional BMT [8]. Unfortunately,
GVHD remains a major limitation of allogeneic
CT, and further advances are required to reduce the
ncidence and severity of this complication. The data
resented here suggest that the induction of cGVHD
s a consequence of the number of G-CSF–modiﬁed
onor T cells infused in conjunction with a non–T cell
hat has been expanded or modiﬁed by G-CSF. Thus,
he limitation of cell doses during allogeneic SCTmay
imit both aGVHD and cGVHD while maintaining
eneﬁcial effects on graft quality.
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